US › Healthcare

Upstream Bio, Inc. (UPB)

US · Healthcare · Biotechnology

$5.31-0.38%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$773,000

Revenue YoY

-17.5%

Net profit

$-39.7M

EPS

$-0.73

EPS estimate

$-0.78

Net margin

-5,136.1%

EPS came in at -0.73 against a street estimate of -0.78 — a beat of 6.4%.

Key statistics

Market cap

$313.8M

Forward P/E

0.0

P/B

1.16

Book value

$4.95

EPS (TTM)

$-2.88

52-week high

$33.68

52-week low

$5.65

50-day MA

$6.84

200-day MA

$13.51

Analyst view

Analysts rate Upstream Bio, Inc. a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $31.14.

Shareholding

Insiders

14.78%

Institutions

92.50%

Largest institutional holders

Fund	Stake
FMR Inc	14.79%
Orbimed Advisors LLC	10.40%
NORGES BANK	6.88%
BlackRock Inc	6.15%
Decheng Capital LLC	4.97%
Enavate Sciences GP, LLC	4.49%
Vanguard Capital Management, LLC	3.42%
Millennium Management LLC	2.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Upstream Bio, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.